Seetharaman Amritha T M, Owens Caroline E, Gangaraju Rajashekhar
Department of Ophthalmology, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Department of Ophthalmology, Anatomy & Neurobiology, Neuroscience Institute, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
J Ocul Pharmacol Ther. 2024 Dec;40(10):617-628. doi: 10.1089/jop.2024.0111. Epub 2024 Oct 2.
Montelukast, a Food and Drug Administration-approved drug for asthma and allergic rhinitis modulates leukotriene (LT) receptors and serves as a critical anti-inflammatory agent. Recent research suggests that the LT signaling pathway targeted by montelukast has broader implications for diseases such as fibrosis, cardiovascular diseases, cancer, cerebrovascular disease, and immune defense. This expanded understanding highlights montelukast's potential for repurposing in conditions involving aberrant stress mechanisms, including ocular diseases marked by inflammation, oxidative stress, ER stress, and apoptosis, among several others. This review delves into montelukast's therapeutic mechanisms across various diseases, draws parallels to ocular conditions, and examines clinical trials and associated adverse effects to underscore the unmet need for cysteinyl LT receptor antagonism by montelukast as an effective therapy for visual deficits.
孟鲁司特是一种经美国食品药品监督管理局批准用于治疗哮喘和过敏性鼻炎的药物，它可调节白三烯（LT）受体，是一种关键的抗炎药。最近的研究表明，孟鲁司特所靶向的LT信号通路在诸如纤维化、心血管疾病、癌症、脑血管疾病和免疫防御等疾病中具有更广泛的影响。这种更深入的理解凸显了孟鲁司特在涉及异常应激机制的病症中重新利用的潜力，这些病症包括以炎症、氧化应激、内质网应激和凋亡等为特征的眼部疾病等多种疾病。本综述深入探讨了孟鲁司特在各种疾病中的治疗机制，将其与眼部疾病进行类比，并审视临床试验及相关不良反应，以强调孟鲁司特作为治疗视力缺陷的有效疗法，对半胱氨酰LT受体拮抗作用仍未满足的需求。
